AxoGen, Inc. (AXGN) Stock Competitors & Peer Comparison
See (AXGN) competitors and their performances in Stock Market.
Peer Comparison Table: Medical - Devices Industry
Detailed financial metrics including price, market cap, P/E ratio, and more.
| Symbol | Price | Change % | Market Cap | P/E Ratio | EPS | Dividend Yield |
|---|---|---|---|---|---|---|
| AXGN | $42.64 | +4.95% | 2.3B | -66.23 | -$0.64 | N/A |
| BSX-PA | $122.18 | +2.37% | 175.4B | 230.53 | $0.53 | N/A |
| ABT | $92.32 | +6.13% | 158B | 25.41 | $3.57 | +2.71% |
| ISRG | $424.63 | +4.26% | 148.4B | 50.78 | $8.25 | N/A |
| SYK | $309.43 | +4.89% | 115.4B | 34.81 | $8.65 | +1.15% |
| MDT | $82.21 | +5.47% | 105.2B | 21.97 | $3.73 | +3.49% |
| BSX | $49.83 | +4.49% | 72.6B | 20.43 | $2.39 | N/A |
| BRKRP | $441.92 | -4.68% | 67.4B | N/A | N/A | +0.33% |
| EW | $89.31 | +3.85% | 50.3B | 47.26 | $1.85 | N/A |
| RMD | $199.36 | +6.92% | 28.2B | 18.74 | $10.37 | +1.25% |
Stock Comparison
AXGN vs BSX-PA Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BSX-PA has a market cap of 175.4B. Regarding current trading prices, AXGN is priced at $42.64, while BSX-PA trades at $122.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BSX-PA's P/E ratio is 230.53. In terms of profitability, AXGN's ROE is -0.21%, compared to BSX-PA's ROE of +0.15%. Regarding short-term risk, AXGN is less volatile compared to BSX-PA. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BSX-PA's competition here
AXGN vs ABT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ABT has a market cap of 158B. Regarding current trading prices, AXGN is priced at $42.64, while ABT trades at $92.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ABT's P/E ratio is 25.41. In terms of profitability, AXGN's ROE is -0.21%, compared to ABT's ROE of +0.12%. Regarding short-term risk, AXGN is less volatile compared to ABT. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ABT's competition here
AXGN vs ISRG Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ISRG has a market cap of 148.4B. Regarding current trading prices, AXGN is priced at $42.64, while ISRG trades at $424.63.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ISRG's P/E ratio is 50.78. In terms of profitability, AXGN's ROE is -0.21%, compared to ISRG's ROE of +0.17%. Regarding short-term risk, AXGN is less volatile compared to ISRG. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ISRG's competition here
AXGN vs SYK Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SYK has a market cap of 115.4B. Regarding current trading prices, AXGN is priced at $42.64, while SYK trades at $309.43.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SYK's P/E ratio is 34.81. In terms of profitability, AXGN's ROE is -0.21%, compared to SYK's ROE of +0.15%. Regarding short-term risk, AXGN is less volatile compared to SYK. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check SYK's competition here
AXGN vs MDT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, MDT has a market cap of 105.2B. Regarding current trading prices, AXGN is priced at $42.64, while MDT trades at $82.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas MDT's P/E ratio is 21.97. In terms of profitability, AXGN's ROE is -0.21%, compared to MDT's ROE of +0.10%. Regarding short-term risk, AXGN is less volatile compared to MDT. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check MDT's competition here
AXGN vs BSX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BSX has a market cap of 72.6B. Regarding current trading prices, AXGN is priced at $42.64, while BSX trades at $49.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BSX's P/E ratio is 20.43. In terms of profitability, AXGN's ROE is -0.21%, compared to BSX's ROE of +0.15%. Regarding short-term risk, AXGN is less volatile compared to BSX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BSX's competition here
AXGN vs BRKRP Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BRKRP has a market cap of 67.4B. Regarding current trading prices, AXGN is priced at $42.64, while BRKRP trades at $441.92.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BRKRP's P/E ratio is N/A. In terms of profitability, AXGN's ROE is -0.21%, compared to BRKRP's ROE of -0.01%. Regarding short-term risk, AXGN is less volatile compared to BRKRP. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BRKRP's competition here
AXGN vs EW Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, EW has a market cap of 50.3B. Regarding current trading prices, AXGN is priced at $42.64, while EW trades at $89.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas EW's P/E ratio is 47.26. In terms of profitability, AXGN's ROE is -0.21%, compared to EW's ROE of +0.11%. Regarding short-term risk, AXGN is less volatile compared to EW. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check EW's competition here
AXGN vs RMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, RMD has a market cap of 28.2B. Regarding current trading prices, AXGN is priced at $42.64, while RMD trades at $199.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas RMD's P/E ratio is 18.74. In terms of profitability, AXGN's ROE is -0.21%, compared to RMD's ROE of +0.24%. Regarding short-term risk, AXGN is less volatile compared to RMD. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check RMD's competition here
AXGN vs DXCM Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, DXCM has a market cap of 28B. Regarding current trading prices, AXGN is priced at $42.64, while DXCM trades at $75.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas DXCM's P/E ratio is 31.15. In terms of profitability, AXGN's ROE is -0.21%, compared to DXCM's ROE of +0.34%. Regarding short-term risk, AXGN is less volatile compared to DXCM. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check DXCM's competition here
AXGN vs PHG Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, PHG has a market cap of 25.3B. Regarding current trading prices, AXGN is priced at $42.64, while PHG trades at $26.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas PHG's P/E ratio is 22.40. In terms of profitability, AXGN's ROE is -0.21%, compared to PHG's ROE of +0.09%. Regarding short-term risk, AXGN is more volatile compared to PHG. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check PHG's competition here
AXGN vs STE Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, STE has a market cap of 20.7B. Regarding current trading prices, AXGN is priced at $42.64, while STE trades at $212.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas STE's P/E ratio is 26.76. In terms of profitability, AXGN's ROE is -0.21%, compared to STE's ROE of +0.11%. Regarding short-term risk, AXGN is less volatile compared to STE. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check STE's competition here
AXGN vs ABMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ABMD has a market cap of 17.2B. Regarding current trading prices, AXGN is priced at $42.64, while ABMD trades at $381.02.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ABMD's P/E ratio is 65.36. In terms of profitability, AXGN's ROE is -0.21%, compared to ABMD's ROE of +0.10%. Regarding short-term risk, AXGN is more volatile compared to ABMD. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check ABMD's competition here
AXGN vs ZBH Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ZBH has a market cap of 16.8B. Regarding current trading prices, AXGN is priced at $42.64, while ZBH trades at $88.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ZBH's P/E ratio is 22.46. In terms of profitability, AXGN's ROE is -0.21%, compared to ZBH's ROE of +0.06%. Regarding short-term risk, AXGN is less volatile compared to ZBH. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ZBH's competition here
AXGN vs SNN Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SNN has a market cap of 13.1B. Regarding current trading prices, AXGN is priced at $42.64, while SNN trades at $30.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SNN's P/E ratio is 21.57. In terms of profitability, AXGN's ROE is -0.21%, compared to SNN's ROE of +0.12%. Regarding short-term risk, AXGN is more volatile compared to SNN. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check SNN's competition here
AXGN vs PEN Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, PEN has a market cap of 12.6B. Regarding current trading prices, AXGN is priced at $42.64, while PEN trades at $321.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas PEN's P/E ratio is 74.06. In terms of profitability, AXGN's ROE is -0.21%, compared to PEN's ROE of +0.12%. Regarding short-term risk, AXGN is more volatile compared to PEN. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check PEN's competition here
AXGN vs SWAV Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SWAV has a market cap of 12.6B. Regarding current trading prices, AXGN is priced at $42.64, while SWAV trades at $334.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SWAV's P/E ratio is 78.76. In terms of profitability, AXGN's ROE is -0.21%, compared to SWAV's ROE of +0.25%. Regarding short-term risk, AXGN is more volatile compared to SWAV. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check SWAV's competition here
AXGN vs ALGN Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ALGN has a market cap of 12.1B. Regarding current trading prices, AXGN is priced at $42.64, while ALGN trades at $170.31.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ALGN's P/E ratio is 28.33. In terms of profitability, AXGN's ROE is -0.21%, compared to ALGN's ROE of +0.11%. Regarding short-term risk, AXGN is less volatile compared to ALGN. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ALGN's competition here
AXGN vs GMED Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, GMED has a market cap of 10.8B. Regarding current trading prices, AXGN is priced at $42.64, while GMED trades at $81.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas GMED's P/E ratio is 18.69. In terms of profitability, AXGN's ROE is -0.21%, compared to GMED's ROE of +0.13%. Regarding short-term risk, AXGN is less volatile compared to GMED. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check GMED's competition here
AXGN vs PODD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, PODD has a market cap of 10.1B. Regarding current trading prices, AXGN is priced at $42.64, while PODD trades at $153.64.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas PODD's P/E ratio is 34.29. In terms of profitability, AXGN's ROE is -0.21%, compared to PODD's ROE of +0.21%. Regarding short-term risk, AXGN is less volatile compared to PODD. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check PODD's competition here
AXGN vs MASI Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, MASI has a market cap of 9.4B. Regarding current trading prices, AXGN is priced at $42.64, while MASI trades at $178.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas MASI's P/E ratio is 44.28. In terms of profitability, AXGN's ROE is -0.21%, compared to MASI's ROE of +0.09%. Regarding short-term risk, AXGN is more volatile compared to MASI. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check MASI's competition here
AXGN vs BRKR Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BRKR has a market cap of 9.1B. Regarding current trading prices, AXGN is priced at $42.64, while BRKR trades at $59.17.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BRKR's P/E ratio is -249.83. In terms of profitability, AXGN's ROE is -0.21%, compared to BRKR's ROE of -0.01%. Regarding short-term risk, AXGN is less volatile compared to BRKR. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BRKR's competition here
AXGN vs BIO-B Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BIO-B has a market cap of 8.7B. Regarding current trading prices, AXGN is priced at $42.64, while BIO-B trades at $321.48.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BIO-B's P/E ratio is 53.40. In terms of profitability, AXGN's ROE is -0.21%, compared to BIO-B's ROE of +0.02%. Regarding short-term risk, AXGN is more volatile compared to BIO-B. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check BIO-B's competition here
AXGN vs BIO Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BIO has a market cap of 8.3B. Regarding current trading prices, AXGN is priced at $42.64, while BIO trades at $306.87.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BIO's P/E ratio is 51.06. In terms of profitability, AXGN's ROE is -0.21%, compared to BIO's ROE of +0.02%. Regarding short-term risk, AXGN is less volatile compared to BIO. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BIO's competition here
AXGN vs GKOS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, GKOS has a market cap of 7.1B. Regarding current trading prices, AXGN is priced at $42.64, while GKOS trades at $122.51.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas GKOS's P/E ratio is -36.87. In terms of profitability, AXGN's ROE is -0.21%, compared to GKOS's ROE of -0.26%. Regarding short-term risk, AXGN is less volatile compared to GKOS. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check GKOS's competition here
AXGN vs NARI Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, NARI has a market cap of 4.7B. Regarding current trading prices, AXGN is priced at $42.64, while NARI trades at $79.97.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas NARI's P/E ratio is -59.24. In terms of profitability, AXGN's ROE is -0.21%, compared to NARI's ROE of -0.00%. Regarding short-term risk, AXGN is more volatile compared to NARI. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check NARI's competition here
AXGN vs LIVN Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, LIVN has a market cap of 4B. Regarding current trading prices, AXGN is priced at $42.64, while LIVN trades at $74.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas LIVN's P/E ratio is 37.61. In terms of profitability, AXGN's ROE is -0.21%, compared to LIVN's ROE of +0.09%. Regarding short-term risk, AXGN is less volatile compared to LIVN. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check LIVN's competition here
AXGN vs AXNX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, AXNX has a market cap of 3.6B. Regarding current trading prices, AXGN is priced at $42.64, while AXNX trades at $70.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas AXNX's P/E ratio is -709.80. In terms of profitability, AXGN's ROE is -0.21%, compared to AXNX's ROE of -0.01%. Regarding short-term risk, AXGN is more volatile compared to AXNX. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check AXNX's competition here
AXGN vs IRTC Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, IRTC has a market cap of 3.5B. Regarding current trading prices, AXGN is priced at $42.64, while IRTC trades at $108.59.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas IRTC's P/E ratio is -126.29. In terms of profitability, AXGN's ROE is -0.21%, compared to IRTC's ROE of -0.21%. Regarding short-term risk, AXGN is less volatile compared to IRTC. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check IRTC's competition here
AXGN vs ITGR Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ITGR has a market cap of 3.1B. Regarding current trading prices, AXGN is priced at $42.64, while ITGR trades at $93.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ITGR's P/E ratio is 23.01. In terms of profitability, AXGN's ROE is -0.21%, compared to ITGR's ROE of +0.08%. Regarding short-term risk, AXGN is less volatile compared to ITGR. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ITGR's competition here
AXGN vs TMDX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, TMDX has a market cap of 2.5B. Regarding current trading prices, AXGN is priced at $42.64, while TMDX trades at $73.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas TMDX's P/E ratio is 16.33. In terms of profitability, AXGN's ROE is -0.21%, compared to TMDX's ROE of +0.42%. Regarding short-term risk, AXGN is less volatile compared to TMDX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check TMDX's competition here
AXGN vs ESTA Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ESTA has a market cap of 2.3B. Regarding current trading prices, AXGN is priced at $42.64, while ESTA trades at $76.16.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ESTA's P/E ratio is -52.03. In terms of profitability, AXGN's ROE is -0.21%, compared to ESTA's ROE of -2.26%. Regarding short-term risk, AXGN is less volatile compared to ESTA. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ESTA's competition here
AXGN vs NUVA Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, NUVA has a market cap of 2.1B. Regarding current trading prices, AXGN is priced at $42.64, while NUVA trades at $39.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas NUVA's P/E ratio is 75.00. In terms of profitability, AXGN's ROE is -0.21%, compared to NUVA's ROE of +0.05%. Regarding short-term risk, AXGN is less volatile compared to NUVA. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check NUVA's competition here
AXGN vs UFPT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, UFPT has a market cap of 1.7B. Regarding current trading prices, AXGN is priced at $42.64, while UFPT trades at $229.08.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas UFPT's P/E ratio is 25.54. In terms of profitability, AXGN's ROE is -0.21%, compared to UFPT's ROE of +0.17%. Regarding short-term risk, AXGN is less volatile compared to UFPT. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check UFPT's competition here
AXGN vs PRCT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, PRCT has a market cap of 1.5B. Regarding current trading prices, AXGN is priced at $42.64, while PRCT trades at $26.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas PRCT's P/E ratio is -14.75. In terms of profitability, AXGN's ROE is -0.21%, compared to PRCT's ROE of -0.28%. Regarding short-term risk, AXGN is less volatile compared to PRCT. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check PRCT's competition here
AXGN vs IART Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, IART has a market cap of 1.4B. Regarding current trading prices, AXGN is priced at $42.64, while IART trades at $17.77.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas IART's P/E ratio is -2.71. In terms of profitability, AXGN's ROE is -0.21%, compared to IART's ROE of -0.48%. Regarding short-term risk, AXGN is less volatile compared to IART. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check IART's competition here
AXGN vs BFLY Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BFLY has a market cap of 1.4B. Regarding current trading prices, AXGN is priced at $42.64, while BFLY trades at $4.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BFLY's P/E ratio is -17.30. In terms of profitability, AXGN's ROE is -0.21%, compared to BFLY's ROE of -0.37%. Regarding short-term risk, AXGN is less volatile compared to BFLY. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BFLY's competition here
AXGN vs TNDM Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, TNDM has a market cap of 1.3B. Regarding current trading prices, AXGN is priced at $42.64, while TNDM trades at $19.91.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas TNDM's P/E ratio is -14.19. In terms of profitability, AXGN's ROE is -0.21%, compared to TNDM's ROE of -0.68%. Regarding short-term risk, AXGN is less volatile compared to TNDM. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check TNDM's competition here
AXGN vs AHCO Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, AHCO has a market cap of 1.3B. Regarding current trading prices, AXGN is priced at $42.64, while AHCO trades at $10.04.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas AHCO's P/E ratio is -16.47. In terms of profitability, AXGN's ROE is -0.21%, compared to AHCO's ROE of -0.05%. Regarding short-term risk, AXGN is less volatile compared to AHCO. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check AHCO's competition here
AXGN vs ENOV Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ENOV has a market cap of 1.3B. Regarding current trading prices, AXGN is priced at $42.64, while ENOV trades at $23.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ENOV's P/E ratio is -1.15. In terms of profitability, AXGN's ROE is -0.21%, compared to ENOV's ROE of -0.60%. Regarding short-term risk, AXGN is less volatile compared to ENOV. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ENOV's competition here
AXGN vs HSKA Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, HSKA has a market cap of 1.3B. Regarding current trading prices, AXGN is priced at $42.64, while HSKA trades at $119.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas HSKA's P/E ratio is -62.49. In terms of profitability, AXGN's ROE is -0.21%, compared to HSKA's ROE of -0.04%. Regarding short-term risk, AXGN is more volatile compared to HSKA. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check HSKA's competition here
AXGN vs ATEC Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ATEC has a market cap of 1.2B. Regarding current trading prices, AXGN is priced at $42.64, while ATEC trades at $8.30.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ATEC's P/E ratio is -9.54. In terms of profitability, AXGN's ROE is -0.21%, compared to ATEC's ROE of -4.43%. Regarding short-term risk, AXGN is less volatile compared to ATEC. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ATEC's competition here
AXGN vs INSP Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, INSP has a market cap of 1.2B. Regarding current trading prices, AXGN is priced at $42.64, while INSP trades at $43.03.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas INSP's P/E ratio is 9.58. In terms of profitability, AXGN's ROE is -0.21%, compared to INSP's ROE of +0.18%. Regarding short-term risk, AXGN is less volatile compared to INSP. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check INSP's competition here
AXGN vs IRMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, IRMD has a market cap of 1.2B. Regarding current trading prices, AXGN is priced at $42.64, while IRMD trades at $94.54.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas IRMD's P/E ratio is 51.13. In terms of profitability, AXGN's ROE is -0.21%, compared to IRMD's ROE of +0.24%. Regarding short-term risk, AXGN is less volatile compared to IRMD. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check IRMD's competition here
AXGN vs AVNS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, AVNS has a market cap of 1.2B. Regarding current trading prices, AXGN is priced at $42.64, while AVNS trades at $25.01.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas AVNS's P/E ratio is -15.62. In terms of profitability, AXGN's ROE is -0.21%, compared to AVNS's ROE of -0.09%. Regarding short-term risk, AXGN is more volatile compared to AVNS. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check AVNS's competition here
AXGN vs SILK Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SILK has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $42.64, while SILK trades at $27.49.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SILK's P/E ratio is -18.96. In terms of profitability, AXGN's ROE is -0.21%, compared to SILK's ROE of -0.35%. Regarding short-term risk, AXGN is more volatile compared to SILK. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check SILK's competition here
AXGN vs FNA Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, FNA has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $42.64, while FNA trades at $13.09.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas FNA's P/E ratio is -19.83. In terms of profitability, AXGN's ROE is -0.21%, compared to FNA's ROE of -0.35%. Regarding short-term risk, AXGN is more volatile compared to FNA. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check FNA's competition here
AXGN vs CNMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CNMD has a market cap of 1.1B. Regarding current trading prices, AXGN is priced at $42.64, while CNMD trades at $35.75.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CNMD's P/E ratio is 19.84. In terms of profitability, AXGN's ROE is -0.21%, compared to CNMD's ROE of +0.05%. Regarding short-term risk, AXGN is less volatile compared to CNMD. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CNMD's competition here
AXGN vs AORT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, AORT has a market cap of 1B. Regarding current trading prices, AXGN is priced at $42.64, while AORT trades at $21.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas AORT's P/E ratio is 83.32. In terms of profitability, AXGN's ROE is -0.21%, compared to AORT's ROE of +0.03%. Regarding short-term risk, AXGN is less volatile compared to AORT. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check AORT's competition here
AXGN vs CSII Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CSII has a market cap of 844M. Regarding current trading prices, AXGN is priced at $42.64, while CSII trades at $20.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CSII's P/E ratio is -20.83. In terms of profitability, AXGN's ROE is -0.21%, compared to CSII's ROE of -0.14%. Regarding short-term risk, AXGN is more volatile compared to CSII. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check CSII's competition here
AXGN vs INMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, INMD has a market cap of 828.2M. Regarding current trading prices, AXGN is priced at $42.64, while INMD trades at $13.66.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas INMD's P/E ratio is 10.09. In terms of profitability, AXGN's ROE is -0.21%, compared to INMD's ROE of +0.13%. Regarding short-term risk, AXGN is more volatile compared to INMD. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check INMD's competition here
AXGN vs LMRI Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, LMRI has a market cap of 791.7M. Regarding current trading prices, AXGN is priced at $42.64, while LMRI trades at $8.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas LMRI's P/E ratio is -21.13. In terms of profitability, AXGN's ROE is -0.21%, compared to LMRI's ROE of -0.15%. Regarding short-term risk, AXGN is less volatile compared to LMRI. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check LMRI's competition here
AXGN vs SSII Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SSII has a market cap of 768.5M. Regarding current trading prices, AXGN is priced at $42.64, while SSII trades at $3.83.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SSII's P/E ratio is -76.80. In terms of profitability, AXGN's ROE is -0.21%, compared to SSII's ROE of -0.23%. Regarding short-term risk, AXGN is less volatile compared to SSII. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check SSII's competition here
AXGN vs CRY Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CRY has a market cap of 725.1M. Regarding current trading prices, AXGN is priced at $42.64, while CRY trades at $17.88.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CRY's P/E ratio is 425.71. In terms of profitability, AXGN's ROE is -0.21%, compared to CRY's ROE of +0.03%. Regarding short-term risk, AXGN is less volatile compared to CRY. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CRY's competition here
AXGN vs CBLL Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CBLL has a market cap of 711.4M. Regarding current trading prices, AXGN is priced at $42.64, while CBLL trades at $19.20.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CBLL's P/E ratio is -11.57. In terms of profitability, AXGN's ROE is -0.21%, compared to CBLL's ROE of -0.38%. Regarding short-term risk, AXGN is less volatile compared to CBLL. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CBLL's competition here
AXGN vs SIBN Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SIBN has a market cap of 659.9M. Regarding current trading prices, AXGN is priced at $42.64, while SIBN trades at $15.37.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SIBN's P/E ratio is -38.15. In terms of profitability, AXGN's ROE is -0.21%, compared to SIBN's ROE of -0.10%. Regarding short-term risk, AXGN is less volatile compared to SIBN. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check SIBN's competition here
AXGN vs SRDX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SRDX has a market cap of 614.5M. Regarding current trading prices, AXGN is priced at $42.64, while SRDX trades at $42.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SRDX's P/E ratio is -34.66. In terms of profitability, AXGN's ROE is -0.21%, compared to SRDX's ROE of -0.13%. Regarding short-term risk, AXGN is more volatile compared to SRDX. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check SRDX's competition here
AXGN vs BVS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BVS has a market cap of 589.4M. Regarding current trading prices, AXGN is priced at $42.64, while BVS trades at $8.98.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BVS's P/E ratio is 21.22. In terms of profitability, AXGN's ROE is -0.21%, compared to BVS's ROE of +0.16%. Regarding short-term risk, AXGN is less volatile compared to BVS. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BVS's competition here
AXGN vs APEN Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, APEN has a market cap of 579.7M. Regarding current trading prices, AXGN is priced at $42.64, while APEN trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas APEN's P/E ratio is -9.43. In terms of profitability, AXGN's ROE is -0.21%, compared to APEN's ROE of -0.85%. Regarding short-term risk, AXGN is less volatile compared to APEN. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check APEN's competition here
AXGN vs TCMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, TCMD has a market cap of 567.7M. Regarding current trading prices, AXGN is priced at $42.64, while TCMD trades at $25.40.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas TCMD's P/E ratio is 28.93. In terms of profitability, AXGN's ROE is -0.21%, compared to TCMD's ROE of +0.10%. Regarding short-term risk, AXGN is less volatile compared to TCMD. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check TCMD's competition here
AXGN vs BWAY Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BWAY has a market cap of 559.7M. Regarding current trading prices, AXGN is priced at $42.64, while BWAY trades at $14.47.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BWAY's P/E ratio is 64.86. In terms of profitability, AXGN's ROE is -0.21%, compared to BWAY's ROE of +0.12%. Regarding short-term risk, AXGN is less volatile compared to BWAY. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BWAY's competition here
AXGN vs CTKB Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CTKB has a market cap of 559.2M. Regarding current trading prices, AXGN is priced at $42.64, while CTKB trades at $4.32.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CTKB's P/E ratio is -7.47. In terms of profitability, AXGN's ROE is -0.21%, compared to CTKB's ROE of -0.21%. Regarding short-term risk, AXGN is less volatile compared to CTKB. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CTKB's competition here
AXGN vs CERS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CERS has a market cap of 559M. Regarding current trading prices, AXGN is priced at $42.64, while CERS trades at $2.71.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CERS's P/E ratio is -55.80. In terms of profitability, AXGN's ROE is -0.21%, compared to CERS's ROE of -0.15%. Regarding short-term risk, AXGN is less volatile compared to CERS. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CERS's competition here
AXGN vs NPCE Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, NPCE has a market cap of 556.4M. Regarding current trading prices, AXGN is priced at $42.64, while NPCE trades at $16.74.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas NPCE's P/E ratio is -25.11. In terms of profitability, AXGN's ROE is -0.21%, compared to NPCE's ROE of -1.21%. Regarding short-term risk, AXGN is less volatile compared to NPCE. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check NPCE's competition here
AXGN vs ZIMV Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ZIMV has a market cap of 535.6M. Regarding current trading prices, AXGN is priced at $42.64, while ZIMV trades at $18.99.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ZIMV's P/E ratio is -27.52. In terms of profitability, AXGN's ROE is -0.21%, compared to ZIMV's ROE of -0.04%. Regarding short-term risk, AXGN is more volatile compared to ZIMV. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check ZIMV's competition here
AXGN vs PACB Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, PACB has a market cap of 506.3M. Regarding current trading prices, AXGN is priced at $42.64, while PACB trades at $1.58.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas PACB's P/E ratio is -3.98. In terms of profitability, AXGN's ROE is -0.21%, compared to PACB's ROE of -4.88%. Regarding short-term risk, AXGN is less volatile compared to PACB. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check PACB's competition here
AXGN vs PMI Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, PMI has a market cap of 498.9M. Regarding current trading prices, AXGN is priced at $42.64, while PMI trades at $0.29.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas PMI's P/E ratio is -0.42. In terms of profitability, AXGN's ROE is -0.21%, compared to PMI's ROE of +4.99%. Regarding short-term risk, AXGN is less volatile compared to PMI. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check PMI's competition here
AXGN vs LAB Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, LAB has a market cap of 488M. Regarding current trading prices, AXGN is priced at $42.64, while LAB trades at $1.21.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas LAB's P/E ratio is -9.62. In terms of profitability, AXGN's ROE is -0.21%, compared to LAB's ROE of -0.21%. Regarding short-term risk, AXGN is less volatile compared to LAB. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check LAB's competition here
AXGN vs KIDS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, KIDS has a market cap of 464.9M. Regarding current trading prices, AXGN is priced at $42.64, while KIDS trades at $17.93.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas KIDS's P/E ratio is -10.77. In terms of profitability, AXGN's ROE is -0.21%, compared to KIDS's ROE of -0.11%. Regarding short-term risk, AXGN is less volatile compared to KIDS. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check KIDS's competition here
AXGN vs VREX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, VREX has a market cap of 440.4M. Regarding current trading prices, AXGN is priced at $42.64, while VREX trades at $10.55.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas VREX's P/E ratio is -5.23. In terms of profitability, AXGN's ROE is -0.21%, compared to VREX's ROE of -0.18%. Regarding short-term risk, AXGN is less volatile compared to VREX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check VREX's competition here
AXGN vs CLPT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CLPT has a market cap of 429.5M. Regarding current trading prices, AXGN is priced at $42.64, while CLPT trades at $13.96.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CLPT's P/E ratio is -14.32. In terms of profitability, AXGN's ROE is -0.21%, compared to CLPT's ROE of -1.41%. Regarding short-term risk, AXGN is less volatile compared to CLPT. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CLPT's competition here
AXGN vs OFIX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, OFIX has a market cap of 416.7M. Regarding current trading prices, AXGN is priced at $42.64, while OFIX trades at $10.57.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas OFIX's P/E ratio is -6.87. In terms of profitability, AXGN's ROE is -0.21%, compared to OFIX's ROE of -0.13%. Regarding short-term risk, AXGN is less volatile compared to OFIX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check OFIX's competition here
AXGN vs VMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, VMD has a market cap of 377.2M. Regarding current trading prices, AXGN is priced at $42.64, while VMD trades at $10.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas VMD's P/E ratio is 26.59. In terms of profitability, AXGN's ROE is -0.21%, compared to VMD's ROE of +0.11%. Regarding short-term risk, AXGN is less volatile compared to VMD. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check VMD's competition here
AXGN vs DCTH Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, DCTH has a market cap of 372.5M. Regarding current trading prices, AXGN is priced at $42.64, while DCTH trades at $11.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas DCTH's P/E ratio is 1079.00. In terms of profitability, AXGN's ROE is -0.21%, compared to DCTH's ROE of +0.01%. Regarding short-term risk, AXGN is less volatile compared to DCTH. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check DCTH's competition here
AXGN vs AVR Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, AVR has a market cap of 355M. Regarding current trading prices, AXGN is priced at $42.64, while AVR trades at $9.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas AVR's P/E ratio is -4.35. In terms of profitability, AXGN's ROE is -0.21%, compared to AVR's ROE of -1.24%. Regarding short-term risk, AXGN is less volatile compared to AVR. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check AVR's competition here
AXGN vs ICCM Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ICCM has a market cap of 347.8M. Regarding current trading prices, AXGN is priced at $42.64, while ICCM trades at $4.95.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ICCM's P/E ratio is -21.54. In terms of profitability, AXGN's ROE is -0.21%, compared to ICCM's ROE of -2.12%. Regarding short-term risk, AXGN is less volatile compared to ICCM. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ICCM's competition here
AXGN vs MASS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, MASS has a market cap of 333.5M. Regarding current trading prices, AXGN is priced at $42.64, while MASS trades at $8.42.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas MASS's P/E ratio is -9.09. In terms of profitability, AXGN's ROE is -0.21%, compared to MASS's ROE of -0.26%. Regarding short-term risk, AXGN is less volatile compared to MASS. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check MASS's competition here
AXGN vs SMLR Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SMLR has a market cap of 310.7M. Regarding current trading prices, AXGN is priced at $42.64, while SMLR trades at $20.33.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SMLR's P/E ratio is 3.92. In terms of profitability, AXGN's ROE is -0.21%, compared to SMLR's ROE of +0.16%. Regarding short-term risk, AXGN is more volatile compared to SMLR. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check SMLR's competition here
AXGN vs ELMD Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ELMD has a market cap of 305.3M. Regarding current trading prices, AXGN is priced at $42.64, while ELMD trades at $37.35.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ELMD's P/E ratio is 31.51. In terms of profitability, AXGN's ROE is -0.21%, compared to ELMD's ROE of +0.22%. Regarding short-term risk, AXGN is more volatile compared to ELMD. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check ELMD's competition here
AXGN vs SENS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SENS has a market cap of 292.8M. Regarding current trading prices, AXGN is priced at $42.64, while SENS trades at $7.07.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SENS's P/E ratio is -3.56. In terms of profitability, AXGN's ROE is -0.21%, compared to SENS's ROE of -1.30%. Regarding short-term risk, AXGN is less volatile compared to SENS. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check SENS's competition here
AXGN vs CATX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CATX has a market cap of 250.3M. Regarding current trading prices, AXGN is priced at $42.64, while CATX trades at $3.24.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CATX's P/E ratio is -2.30. In terms of profitability, AXGN's ROE is -0.21%, compared to CATX's ROE of -0.42%. Regarding short-term risk, AXGN is less volatile compared to CATX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CATX's competition here
AXGN vs SGHT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SGHT has a market cap of 250.3M. Regarding current trading prices, AXGN is priced at $42.64, while SGHT trades at $4.60.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SGHT's P/E ratio is -6.57. In terms of profitability, AXGN's ROE is -0.21%, compared to SGHT's ROE of -0.59%. Regarding short-term risk, AXGN is less volatile compared to SGHT. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check SGHT's competition here
AXGN vs MGRM Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, MGRM has a market cap of 243.8M. Regarding current trading prices, AXGN is priced at $42.64, while MGRM trades at $6.00.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas MGRM's P/E ratio is -11.11. In terms of profitability, AXGN's ROE is -0.21%, compared to MGRM's ROE of -1.11%. Regarding short-term risk, AXGN is more volatile compared to MGRM. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check MGRM's competition here
AXGN vs TMCI Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, TMCI has a market cap of 239.4M. Regarding current trading prices, AXGN is priced at $42.64, while TMCI trades at $3.70.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas TMCI's P/E ratio is -3.84. In terms of profitability, AXGN's ROE is -0.21%, compared to TMCI's ROE of -0.69%. Regarding short-term risk, AXGN is less volatile compared to TMCI. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check TMCI's competition here
AXGN vs NVRO Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, NVRO has a market cap of 224.1M. Regarding current trading prices, AXGN is priced at $42.64, while NVRO trades at $5.84.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas NVRO's P/E ratio is -1.91. In terms of profitability, AXGN's ROE is -0.21%, compared to NVRO's ROE of -0.43%. Regarding short-term risk, AXGN is more volatile compared to NVRO. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check NVRO's competition here
AXGN vs RXST Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, RXST has a market cap of 211.1M. Regarding current trading prices, AXGN is priced at $42.64, while RXST trades at $5.18.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas RXST's P/E ratio is -4.51. In terms of profitability, AXGN's ROE is -0.21%, compared to RXST's ROE of -0.17%. Regarding short-term risk, AXGN is less volatile compared to RXST. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check RXST's competition here
AXGN vs EYES Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, EYES has a market cap of 210M. Regarding current trading prices, AXGN is priced at $42.64, while EYES trades at $4.14.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas EYES's P/E ratio is N/A. In terms of profitability, AXGN's ROE is -0.21%, compared to EYES's ROE of -2.64%. Regarding short-term risk, AXGN is less volatile compared to EYES. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check EYES's competition here
AXGN vs PROF Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, PROF has a market cap of 205.8M. Regarding current trading prices, AXGN is priced at $42.64, while PROF trades at $6.79.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas PROF's P/E ratio is -5.48. In terms of profitability, AXGN's ROE is -0.21%, compared to PROF's ROE of -0.71%. Regarding short-term risk, AXGN is less volatile compared to PROF. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check PROF's competition here
AXGN vs ANIK Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, ANIK has a market cap of 196.8M. Regarding current trading prices, AXGN is priced at $42.64, while ANIK trades at $14.38.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas ANIK's P/E ratio is -18.72. In terms of profitability, AXGN's ROE is -0.21%, compared to ANIK's ROE of -0.08%. Regarding short-term risk, AXGN is less volatile compared to ANIK. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check ANIK's competition here
AXGN vs BSGM Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, BSGM has a market cap of 191.1M. Regarding current trading prices, AXGN is priced at $42.64, while BSGM trades at $6.10.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas BSGM's P/E ratio is -5.81. In terms of profitability, AXGN's ROE is -0.21%, compared to BSGM's ROE of +17.60%. Regarding short-term risk, AXGN is less volatile compared to BSGM. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check BSGM's competition here
AXGN vs APYX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, APYX has a market cap of 179.6M. Regarding current trading prices, AXGN is priced at $42.64, while APYX trades at $4.39.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas APYX's P/E ratio is -19.50. In terms of profitability, AXGN's ROE is -0.21%, compared to APYX's ROE of -0.91%. Regarding short-term risk, AXGN is less volatile compared to APYX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check APYX's competition here
AXGN vs QTRX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, QTRX has a market cap of 179M. Regarding current trading prices, AXGN is priced at $42.64, while QTRX trades at $3.80.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas QTRX's P/E ratio is -1.62. In terms of profitability, AXGN's ROE is -0.21%, compared to QTRX's ROE of -0.35%. Regarding short-term risk, AXGN is less volatile compared to QTRX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check QTRX's competition here
AXGN vs MDGS Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, MDGS has a market cap of 178.9M. Regarding current trading prices, AXGN is priced at $42.64, while MDGS trades at $2.36.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas MDGS's P/E ratio is -0.27. In terms of profitability, AXGN's ROE is -0.21%, compared to MDGS's ROE of -0.51%. Regarding short-term risk, AXGN is less volatile compared to MDGS. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check MDGS's competition here
AXGN vs EDAP Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, EDAP has a market cap of 178.2M. Regarding current trading prices, AXGN is priced at $42.64, while EDAP trades at $4.76.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas EDAP's P/E ratio is -5.80. In terms of profitability, AXGN's ROE is -0.21%, compared to EDAP's ROE of -1.49%. Regarding short-term risk, AXGN is less volatile compared to EDAP. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check EDAP's competition here
AXGN vs INGN Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, INGN has a market cap of 170.8M. Regarding current trading prices, AXGN is priced at $42.64, while INGN trades at $6.52.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas INGN's P/E ratio is -6.93. In terms of profitability, AXGN's ROE is -0.21%, compared to INGN's ROE of -0.13%. Regarding short-term risk, AXGN is less volatile compared to INGN. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check INGN's competition here
AXGN vs QIPT Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, QIPT has a market cap of 162.3M. Regarding current trading prices, AXGN is priced at $42.64, while QIPT trades at $3.65.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas QIPT's P/E ratio is -15.87. In terms of profitability, AXGN's ROE is -0.21%, compared to QIPT's ROE of -0.10%. Regarding short-term risk, AXGN is more volatile compared to QIPT. This indicates potentially higher risk in terms of short-term price fluctuations for AXGN.Check QIPT's competition here
AXGN vs CVRX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, CVRX has a market cap of 156M. Regarding current trading prices, AXGN is priced at $42.64, while CVRX trades at $5.89.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas CVRX's P/E ratio is -2.93. In terms of profitability, AXGN's ROE is -0.21%, compared to CVRX's ROE of -1.21%. Regarding short-term risk, AXGN is less volatile compared to CVRX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check CVRX's competition here
AXGN vs NNOX Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, NNOX has a market cap of 144.1M. Regarding current trading prices, AXGN is priced at $42.64, while NNOX trades at $2.05.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas NNOX's P/E ratio is -1.78. In terms of profitability, AXGN's ROE is -0.21%, compared to NNOX's ROE of -0.47%. Regarding short-term risk, AXGN is less volatile compared to NNOX. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check NNOX's competition here
AXGN vs SNWV Comparison June 2026
AXGN plays a significant role within the Healthcare sector. Its performance reflects broader market trends and attracts considerable investor interest.
Comparing market capitalization, AXGN stands at 2.3B. In comparison, SNWV has a market cap of 135M. Regarding current trading prices, AXGN is priced at $42.64, while SNWV trades at $15.50.
To assess relative profitability and valuation, we examine the Return on Equity (ROE) and Price-to-Earnings (P/E) ratios.
AXGN currently has a P/E ratio of -66.23, whereas SNWV's P/E ratio is 16.35. In terms of profitability, AXGN's ROE is -0.21%, compared to SNWV's ROE of -4.51%. Regarding short-term risk, AXGN is less volatile compared to SNWV. This indicates potentially lower risk in terms of short-term price fluctuations for AXGN.Check SNWV's competition here